PERSONAL CFO SOLUTIONS, LLC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 140 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.

Quarter-by-quarter ownership
PERSONAL CFO SOLUTIONS, LLC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$472,632
+0.6%
66,7560.0%0.09%
-2.1%
Q2 2023$469,962
-16.8%
66,756
-1.5%
0.10%
-18.8%
Q1 2023$565,085
-27.0%
67,756
+0.5%
0.12%
-28.7%
Q4 2022$773,637
-8.9%
67,3900.0%0.16%
-23.0%
Q3 2022$849,000
+19.6%
67,390
+0.5%
0.21%
+27.5%
Q2 2022$710,000
-60.0%
67,088
-38.6%
0.17%
-52.3%
Q1 2022$1,775,000
+17.4%
109,1880.0%0.35%
+23.7%
Q4 2021$1,512,000
-3.6%
109,1880.0%0.28%
-12.1%
Q3 2021$1,569,000
-11.2%
109,188
-2.2%
0.32%
-11.0%
Q2 2021$1,766,000
+42.8%
111,678
-8.2%
0.36%
+35.6%
Q1 2021$1,237,000
+57.8%
121,678
+15.7%
0.27%
+37.6%
Q4 2020$784,000105,178
+15.4%
0.19%
Q3 2020$0
-100.0%
91,178
+10.3%
0.00%
-100.0%
Q2 2020$394,000
+126.4%
82,678
-5.1%
0.12%
+88.7%
Q1 2020$174,000
+58.2%
87,078
+172.1%
0.06%
+93.8%
Q4 2019$110,00032,0000.03%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q4 2019
NameSharesValueWeighting ↓
VHCP Management, LLC 1,744,356$18,455,0009.59%
RA Capital Management 4,347,456$45,996,0003.30%
Cormorant Asset Management, LP 1,168,000$12,357,0002.84%
Baker Brothers Advisors 5,867,031$62,073,0000.79%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 907,920$9,606,0000.39%
QVT Financial LP 525,734$5,562,0000.32%
EAM Investors, LLC 114,548$1,212,0000.22%
FRANKLIN STREET ADVISORS INC /NC 93,000$984,0000.20%
THB ASSET MANAGEMENT 301,529$3,190,0000.19%
TPG Group Holdings (SBS) Advisors, Inc. 1,162,269$12,297,0000.13%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders